We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

89 hedge funds and large institutions have $208M invested in TScan Therapeutics in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

53% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 17

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

11% more funds holding

Funds holding: 80 → 89 (+9)

0.6% more ownership

Funds ownership: 85.31% → 85.9% (+0.6%)

14% less capital invested

Capital invested by funds: $242M → $208M (-$34.1M)

Holders
89
Holders Change
+9
Holders Change %
+11.25%
% of All Funds
1.28%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
20
Increased
26
Reduced
17
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Checkpoint Capital
California
+$4.98M
2
Northern Trust
Northern Trust
Illinois
+$1.37M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.29M
4
BlackRock
BlackRock
New York
+$1.03M
5
State Street
State Street
Massachusetts
+$895K

Top Sellers

Rank Fund Capital Flow
1
LP
LMR Partners
United Kingdom
-$3.58M
2
Invesco
Invesco
Georgia
-$2.91M
3
PBA
Paradigm Biocapital Advisors
New York
-$2.07M
4
Citadel Advisors
Citadel Advisors
Florida
-$924K
5
Marshall Wace
Marshall Wace
United Kingdom
-$859K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$629K +$214K +35,404 +39%
Charles Schwab
27
Charles Schwab
California
$562K – – –
WP
28
Woodline Partners
California
$541K -$331K -54,908 -34%
Jacobs Levy Equity Management
29
Jacobs Levy Equity Management
New Jersey
$515K +$624K +103,440 New
Stifel Financial
30
Stifel Financial
Missouri
$494K +$22.5K +3,733 +4%
Bank of America
31
Bank of America
North Carolina
$484K +$322K +53,429 +122%
Jane Street
32
Jane Street
New York
$468K -$31.1K -5,160 -5%
NW
33
NewEdge Wealth
Pennsylvania
$455K – – –
Bank of New York Mellon
34
Bank of New York Mellon
New York
$440K -$171K -28,344 -24%
Walleye Capital
35
Walleye Capital
New York
$422K -$139K -22,966 -21%
Renaissance Technologies
36
Renaissance Technologies
New York
$369K -$36.2K -6,000 -8%
LP
37
LMR Partners
United Kingdom
$358K -$3.58M -593,729 -89%
N
38
Nuveen
North Carolina
$348K – – –
Barclays
39
Barclays
United Kingdom
$289K +$271K +44,903 +341%
ECM
40
ExodusPoint Capital Management
New York
$278K +$337K +55,845 New
Qube Research & Technologies (QRT)
41
Qube Research & Technologies (QRT)
United Kingdom
$272K -$144K -23,821 -30%
TCA
42
Troluce Capital Advisors
Puerto Rico
$264K -$241K -39,918 -43%
Millennium Management
43
Millennium Management
New York
$242K +$125K +20,783 +75%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$235K +$2.03K +336 +0.7%
PFCS
45
Pale Fire Capital SE
Czech Republic
$218K +$134K +22,150 +103%
BCM
46
Bridgeway Capital Management
Texas
$191K – – –
DIM
47
DC Investments Management
Virginia
$177K – – –
CSS
48
Cubist Systematic Strategies
Connecticut
$160K +$194K +32,137 New
JP Morgan Chase
49
JP Morgan Chase
New York
$158K +$93.2K +15,441 +94%
Citigroup
50
Citigroup
New York
$138K +$117K +19,347 +229%
1
2
3 4

TCRX Hedge Fund Activity: Q3 2024 in Review

89 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q3 2024, worth a combined $208M — down 14% from $242M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new TCRX positions and 11 closed out — a net gain of 9 holders — while 26 added to existing stakes and 17 trimmed.

The largest buyer was Checkpoint Capital, opening a new position worth an estimated $4.98M. The largest seller was LMR Partners, cutting an estimated $3.58M.

  • 89 institutional investors held TScan Therapeutics (TCRX) as of Q3 2024, up from 80 in Q2 2024.
  • Funds reported $208M of TScan Therapeutics stock for Q3 2024, down 14% quarter-over-quarter.
  • 20 funds opened new TScan Therapeutics positions in Q3 2024 and 11 closed out, a net change of +9 holders.
  • The largest TScan Therapeutics buyer in Q3 2024 was Checkpoint Capital, an estimated $4.98M added.
  • The largest TScan Therapeutics seller in Q3 2024 was LMR Partners, an estimated $3.58M sold.

Based on aggregated 13F filings for Q3 2024.